Heymach, J., Hanrahan, E., Mann, H., Langmuir, P., Natale, R., Johnson, B., . . . Ryan, A. (2008). Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC.
Chicago Style (17th ed.) CitationHeymach, J., E. Hanrahan, H. Mann, P. Langmuir, R. Natale, B. Johnson, R. Herbst, and A. Ryan. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.
MLA引文Heymach, J., et al. Baseline VEGF as a Potential Predictive Biomarker of Vandetanib Clinical Benefit in Patients with Advanced NSCLC. 2008.
警告:這些引文格式不一定是100%准確.